DiaGenic ASA Patent Allowed in Canada
Published: Apr 11, 2013
OSLO, Norway--(BUSINESS WIRE)--Regulatory News: DiaGenic (OSE:DIAG) has received notice of allowance for its Canadian family 2 patent application. The allowed claims cover the use of a set of gene sequences in blood essential for the diagnosis of, among other diseases, Alzheimer’s disease and stages thereof. The patent when granted will be valid until 2023.